A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

Lund University Hospital390 enrolled

Overview

The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy.

Chemotherapy will be given in accordance with local or regional guidelines but shall include a platinum drug + any topoisomerase inhibitor. Within these limits the study will accept different local variants as long as each centre remains consistent to its declared standard chemotherapy regimen. The recommended regimen is carboplatin or cisplatin plus etoposide q3 weeks for 4 cycles but up to 6 cycles is allowed. Local dosages and dose reduction schedules will be used.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

390

Conditions

Small Cell Lung Cancer

Interventions

cisplatinum or carboplatin and e.g.etoposide.DRUG

Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.

cisplatinum or carboplatin and e.g.etoposide+enoxaparinDRUG

Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Histologically or cytologically verified SCLC, all stages 2. WHO performance status 0, 1, 2 or 3 3. Age 18 years or older 4. Intention and feasibility to treat with chemotherapy consisting of platinum + topoisomerase inhibitor. 5. Platelets \>100 x109 /L 6. Signed informed consent 7. PK (prothrombin complex) INR and APTT within normal ranges. Exclusion Criteria: 1. Prior systemic chemotherapy for lung cancer. 2. Concomitant anticoagulation treatment, except for ASA or clopidogrel 3. Active overt bleeding of clinical importance or at high risk (e.g. earlier observed haemorrhage in a brain metastasis, severe coagulopathy as haemophilia, severe liver dysfunction with impaired coagulation, acute peptic ulcer, and within the last 3 months suffered from intracranial haemorrhage, or surgery in the central nervous system). 4. Any other known contraindication for enoxaparine ( e.g. Hypersensitivity against enoxaparine and its derivatives). 5. Pregnancy or breast-feeding 6. Fertile women not using effective contraceptives or men who do not agree to use effective contraception during the treatment period. 7. Treatment with any other investigational agent, or participation in any other clinical trial.

Locations (16)

Gävle hospital

Gävle, Sweden

Sahlgrenska University Hospital

Gothenburg, Sweden

Helsingborg Hospital

Helsingborg, Sweden

Outcomes

Primary Outcomes

Significant increase of overall survival

Time frame: At follow up 1 year after treatment

Secondary Outcomes

Toxicity

Time frame: During treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.